BGX-Ki-67 Index as a Supplementary Marker to MIB-1 Index, Enabling More Precise Distinction Between Luminal A and B Subtypes of Breast Carcinoma and Eliminating the Problem of Membranous/Cytoplasmic MIB-1 Staining.

CONCLUSIONS: In carcinomas with membranous/cytoplasmic MIB-1 staining, additional assessment of BGXLI is recommended. It may help in defining breast cancer subtype and in selection of individuals at risk who, despite appropriate therapy, would benefit from more frequent controls aimed at earlier implementation of second-line treatment.
PMID: 25696801 [PubMed - in process]

Source: Clinical Breast Cancer - February 21, 2015 Category: Cancer & Oncology Authors: Niemiec J, Adamczyk A, Ambicka A, Mucha-Małecka A, Wysocki WM, Majchrzyk K, Ryś J Tags: Am J Clin Pathol Source Type: research